Secondary progressive multiple sclerosis and Muscle function loss

Summary:

Muscle function loss is found among people with Secondary progressive multiple sclerosis, especially for people who are female, 40-49 old.

The study analyzes which people have Muscle function loss with Secondary progressive multiple sclerosis. It is created by eHealthMe based on reports of 60 people who have Secondary progressive multiple sclerosis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Secondary progressive multiple sclerosis?

Secondary progressive multiple sclerosis (a stage of ms which comes after relapsing remitting ms in many cases) is found to be associated with 139 drugs and 131 conditions by eHealthMe. Check the latest studies of Secondary progressive multiple sclerosis.

What is Muscle function loss?

Muscle function loss is found to be associated with 1,000 drugs and 1,520 conditions by eHealthMe. Check the latest studies of Muscle function loss.

On Jul, 21, 2026

60 people who have Secondary Progressive Multiple Sclerosis and Muscle Function Loss are studied.

Would you have Muscle function loss when you have Secondary progressive multiple sclerosis?

Gender of people who have Secondary Progressive Multiple Sclerosis and experienced Muscle Function Loss *:

female: 71.67 %
male: 28.33 %

Age of people who have Secondary Progressive Multiple Sclerosis and experienced Muscle Function Loss *:

Common co-existing conditions for these people *:

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 14 people, 23.33%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 11 people, 18.33%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 6 people, 10.00%
Clinically Isolated Syndrome (individual's first neurological episode, caused by inflammation or demyelination of nerve tissue): 5 people, 8.33%
Iron Deficiency Anaemia: 4 people, 6.67%
High Blood Pressure: 3 people, 5.00%
Insomnia (sleeplessness): 2 people, 3.33%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 2 people, 3.33%
Osteoporosis (bones weak and more likely to break): 2 people, 3.33%
Fatigue (feeling of tiredness): 2 people, 3.33%

Common drugs taken by these people *:

Mayzent: 20 people, 33.33%
Betaseron: 15 people, 25.00%
Gilenya: 8 people, 13.33%
Ampyra: 7 people, 11.67%
Baclofen: 7 people, 11.67%
Tecfidera: 6 people, 10.00%
Tysabri: 5 people, 8.33%
Kesimpta: 5 people, 8.33%
Fexofenadine Hydrochloride: 3 people, 5.00%
Keppra: 3 people, 5.00%

Common symptoms for these people *:

Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 25 people, 41.67%
Weakness: 18 people, 30.00%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 14 people, 23.33%
Gait Disturbance: 13 people, 21.67%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 11 people, 18.33%
Headache (pain in head): 10 people, 16.67%
Fatigue (feeling of tiredness): 9 people, 15.00%
Hemiparesis (weakness on one side of the body): 9 people, 15.00%
Lymphopenia (an abnormally low level of lymphocytes in the blood): 8 people, 13.33%
Urinary Tract Infection: 8 people, 13.33%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Muscle function loss?

- Check whether Muscle function loss is associated with a drug or a condition

Related studies:

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Muscle function loss and Secondary progressive multiple sclerosis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.